Primary summaries confirmed that an mRNA-based personalized cancer vaccine combined with immune checkpoint therapy shows substantial tumor control in a Phase 2 clinical trial.
Published accounts described how an mRNA-based personalized cancer vaccine combined with immune checkpoint therapy shows substantial tumor control in a Phase 2 clinical trial.
Primary summaries confirmed that an mRNA-based personalized cancer vaccine combined with immune checkpoint therapy shows substantial tumor control in a Phase 2 clinical trial.
Quantitative details referenced in the item include 2 .
Available records indicate an mRNA-based personalized cancer vaccine combined with immune checkpoint therapy shows substantial tumor control in a Phase 2 clinical trial.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medicalnewstoday.com/news